These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37164450)

  • 1. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.
    Zhang G; Lan B; Zhang X; Lin M; Liu Y; Chen J; Guo F
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
    Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
    Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
    Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
    Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
    Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
    Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
    Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
    Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
    Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
    J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trans-Regulation of Alternative
    Larsen TV; Maansson CT; Daugaard TF; Andresen BS; Sorensen BS; Nielsen AL
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
    Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
    J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
    Greenleaf AL
    Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation.
    Schmitz M; Kaltheuner IH; Anand K; Düster R; Moecking J; Monastyrskyi A; Duckett DR; Roush WR; Geyer M
    J Biol Chem; 2024 Jan; 300(1):105501. PubMed ID: 38016516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer.
    Li Z; Xue H; Li J; Zheng Z; Liu Z; Dong X; Wang H; Chen J; Xu S
    J Exp Clin Cancer Res; 2024 Mar; 43(1):89. PubMed ID: 38520004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cdk12 and Cdk13 regulate axonal elongation through a common signaling pathway that modulates Cdk5 expression.
    Chen HR; Lin GT; Huang CK; Fann MJ
    Exp Neurol; 2014 Nov; 261():10-21. PubMed ID: 24999027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 15. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 16. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
    Sun R; Wei T; Ding D; Zhang J; Chen S; He HH; Wang L; Huang H
    Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2205509119. PubMed ID: 36129942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
    Dubbury SJ; Boutz PL; Sharp PA
    Nature; 2018 Dec; 564(7734):141-145. PubMed ID: 30487607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.